Walgreens Nasal Spray Recall: 41K+ Bottles Contaminated

What was recalled and where it was sold

Walgreens pulled two specific lots of its Saline Nasal Spray with Xylitol — the 1.5-ounce (45 mL) bottles bearing NDC 0363-3114-01. The recall covers Lot 71409 (exp. 02/28/2027) and Lot 71861 (exp. 08/31/2027) and applies to products sold in Walgreens stores nationwide and via its online inventory. For the official municipal notice, see the City of Taunton civic alert, and for media reporting see Fox Business.

Why the product was recalled

Testing identified the presence of Pseudomonas lactis in samples from the two affected lots. Although Pseudomonas lactis is more commonly linked to dairy spoilage and raw milk, any non-sterile microorganism in a nasal product is cause for concern because the spray contacts the nasal mucosa — a direct route to vulnerable tissues. The manufacturer, Medical Products Laboratories, initiated the voluntary recall under FDA guidance.

“The presence of any non-sterile microbes in a nasal product is concerning because the spray is applied directly to the nasal passages.”

FDA classification and what it means

The FDA labeled this action a Class II recall, indicating that the product may cause temporary or medically reversible adverse health consequences; serious outcomes are considered unlikely. Public notices state no illnesses have been linked to these lots as of the latest reports, but officials urge caution for people with weakened immune systems or chronic respiratory disease. See reporting in Supermarket News and Fox Business.

Consumer guidance and steps to take now

Walgreens and municipal notices advise consumers to:

• Stop using any bottle that matches Lot 71409 (exp. 02/28/2027) or Lot 71861 (exp. 08/31/2027).
• Check the bottom or label of each bottle for the lot number and expiration date before use.
• Return affected bottles to Walgreens for a refund.
• Contact your healthcare provider if you used the spray and feel unwell; people with COPD, asthma, immunosuppression, or other chronic respiratory conditions should be especially cautious.

For more consumer details and local guidance, see the City of Taunton civic alert and reporting from Scripps News.

Questions left unanswered

Investigative reporters and public health advocates note several gaps in the public record that remain unaddressed by official notices:

• When and how the contamination was first detected — the timeline of testing is not public.
• Whether routine sterility testing failed to catch the bacterium earlier, or whether contamination occurred later in distribution or storage.
• Whether other products from the same supplier were subject to similar testing or additional recalls.

Public safety experts emphasize these questions because they influence how quickly contaminated products can be isolated and how confident consumers can be in related over-the-counter items. See reporting in Supermarket News for more context.

Manufacturer and supply-chain notes

Medical Products Laboratories of Philadelphia initiated the voluntary recall after testing indicated a contamination risk. The recall under FDA guidance indicates regulator involvement, but public notices do not provide a full timeline of FDA inspections or corrective steps. Retailers and suppliers must maintain good manufacturing practices and sterility testing for mucous-membrane-contact products; lapses can erode consumer trust, particularly during cold and flu season. See Supermarket News for supplier coverage.

Timing and context

The recall was announced in late November 2025 — a period when consumers commonly use nasal sprays for colds, allergies, and sinus care. That timing raises concern that some consumers may have already used product from the impacted lots prior to the recall, though no illnesses have been publicly linked to the lots to date. Officials continue to advise heightened vigilance for people with chronic illnesses; see media reporting at Fox Business and the municipal notice at the City of Taunton civic alert.

Implications for the United States

Economic and retail impact: The recall affects 41,328 bottles — a small slice of the nasal-spray market but a meaningful event for the supplier and Walgreens’ private-label trust. Refunds and product removals carry short-term costs and could prompt retailers to tighten supplier testing oversight.

Public health and patient safety: The incident highlights that products contacting mucous membranes must meet strict microbial limits. Even with a Class II designation and no reported illnesses so far, clinicians and health departments should monitor for possible linked respiratory infections.

Policy and regulatory considerations: The voluntary recall under FDA guidance demonstrates a functioning regulatory channel, but limited public detail on contamination source may spur calls for clearer reporting standards from manufacturers and retailers.

Practical effects for consumers

Shoppers should inspect any Walgreens Saline Nasal Spray with Xylitol at home. If the lot number and expiration date match Lot 71409 (exp. 02/28/2027) or Lot 71861 (exp. 08/31/2027), stop using it and return it to Walgreens for a refund. Those with immune suppression or chronic lung disease who used the spray and feel unwell should contact their healthcare provider without delay.

Sources and further reading

• Fox Business: Over 41K Walgreens nasal spray recalled over contamination risk
• Supermarket News: Walgreens recalls over 41K nasal spray bottles
• MyParisTexas: Walgreens Saline Nasal Spray with Xylitol recalled due to contamination
• Scripps News: Nasal spray recalled over contamination concerns
• City of Taunton civic alert (recall notice)

For consumer questions, check Walgreens’ website or contact store customer service, and consult your healthcare provider if you believe you may have been exposed to the recalled product.